[go: up one dir, main page]

PE20070643A1 - Composiciones farmaceuticas que comprenden buprenorfina - Google Patents

Composiciones farmaceuticas que comprenden buprenorfina

Info

Publication number
PE20070643A1
PE20070643A1 PE2006001462A PE2006001462A PE20070643A1 PE 20070643 A1 PE20070643 A1 PE 20070643A1 PE 2006001462 A PE2006001462 A PE 2006001462A PE 2006001462 A PE2006001462 A PE 2006001462A PE 20070643 A1 PE20070643 A1 PE 20070643A1
Authority
PE
Peru
Prior art keywords
agent
pyrrolidone
formulation
pharmaceutical composition
propylene glycol
Prior art date
Application number
PE2006001462A
Other languages
English (en)
Inventor
Robert D Simmons
Allan Weingarten
Yuping Li
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37745944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of PE20070643A1 publication Critical patent/PE20070643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) BUPRENORFINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1% A 10% DE LA FORMULACION; B) UN SOLVENTE QUE CONSISTE EN UNA FASE ACUOSA Y EN UNA FASE ORGANICA TAL COMO 2-PIRROLIDONA, DIMETILFORMAMIDA, N-METIL-PIRROLIDONA, PROPILEN GLICOL, ENTRE OTROS, QUE SE ENCUENTRA EN UNA CANTIDAD DE 10% A 75% EN PESO DE LA FORMULACION; C) UN AGENTE MEJORADOR DE PENETRACION QUE INCLUYE COMPONENTES LIPOFILICOS Y/O HIDROFILICOS TAL COMO MONOLAURATO DE PROPILEN GLICOL, MENTOL, ETANOL, LAURIL ALCOHOL, ENTRE OTROS; D) UN AGENTE ESTABILIZANTE TAL COMO HIDROXIANISOL BUTILADO (BHA), HIDROXITOLUENO BUTILADO (BHT) Y MONOTIOGLICEROL SODICO; E) UN AGENTE CONSERVANTE TAL COMO METILPARABENO, PROPILPARABENO, ENTRE OTROS; F) UN AGENTE MEJORADOR DE LA VISCOSIDAD TAL COMO HIDROXIPROPILCELULOSA; G) UN ANALGESICO NO OPIOIDE TAL COMO ACIDO ACETILSALICILICO, CELECOXIB, PIROXICAM, ENTRE OTROS. DICHA COMPOSICION FARMACEUTICA TIENE UN pH DE 3 A 10, SIENDO UTIL PARA LA ANALGESIA SISTEMICA MEDIANTE ADMINISTRACION OTICA Y TRANSDERMICA
PE2006001462A 2005-11-21 2006-11-16 Composiciones farmaceuticas que comprenden buprenorfina PE20070643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73852405P 2005-11-21 2005-11-21

Publications (1)

Publication Number Publication Date
PE20070643A1 true PE20070643A1 (es) 2007-08-10

Family

ID=37745944

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001462A PE20070643A1 (es) 2005-11-21 2006-11-16 Composiciones farmaceuticas que comprenden buprenorfina

Country Status (17)

Country Link
US (2) US20070117828A1 (es)
EP (2) EP1954275A2 (es)
JP (2) JP2009516687A (es)
KR (1) KR20080071185A (es)
CN (1) CN101312730A (es)
AR (1) AR058193A1 (es)
AU (1) AU2006316607A1 (es)
BR (1) BRPI0618891A2 (es)
CA (2) CA2630072A1 (es)
EC (1) ECSP088461A (es)
NO (1) NO20082833L (es)
NZ (1) NZ568313A (es)
PE (1) PE20070643A1 (es)
RU (1) RU2008124805A (es)
TW (1) TW200738240A (es)
WO (2) WO2007061739A2 (es)
ZA (2) ZA200804305B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709410A2 (pt) * 2006-03-20 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético
KR20140038575A (ko) * 2006-03-28 2014-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
MX2010004373A (es) * 2007-11-01 2010-05-05 Bausch & Lomb Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos.
CA2728727C (en) * 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
WO2010072398A2 (en) 2008-12-22 2010-07-01 Boehringer Ingelheim Limited Veterinary formulations
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CA2808628A1 (en) * 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
CA2808237C (en) * 2010-09-03 2019-08-06 Abbott Laboratories High dose buprenorphine compositions and use as analgesic
CA2804797C (en) * 2010-10-25 2014-12-23 University Of Manitoba Therapeutic compositions for diabetic symmetrical polyneuropathy and/or tactile allodynia
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
WO2014160702A1 (en) * 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
EP2983668A4 (en) * 2013-04-08 2017-01-11 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
SG11201703632WA (en) 2014-11-07 2017-06-29 Indivior Uk Ltd Buprenorphine dosing regimens
CA3003293A1 (en) * 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
MY196269A (en) * 2016-09-13 2023-03-24 Alar Pharmaceuticals Inc Sustained-Release Buprenorphine Formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
GB201716830D0 (en) * 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
BR112020007808A2 (pt) 2017-10-20 2020-10-20 Chiesi Farmaceutici S.P.A. formulações farmacêuticas que compreendem um agonista de receptor de opioide como ingrediente ativo, métodos de fabricação e usos terapêuticos destas
US11419866B2 (en) * 2018-01-22 2022-08-23 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
EP4408394A1 (en) * 2021-09-30 2024-08-07 Elanco Us Inc. Stable formulations of buprenorphine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6384043B1 (en) * 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
PT889723E (pt) * 1996-03-25 2002-11-29 Lohmann Therapie Syst Lts Sistema terapeutico transdermico com pequena espressura da zona de aplicacao e elevada flexibilidade assim como processo de producao
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
EP1272035A1 (en) * 2000-07-13 2003-01-08 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition

Also Published As

Publication number Publication date
CA2630072A1 (en) 2007-05-31
ECSP088461A (es) 2008-06-30
US20070117828A1 (en) 2007-05-24
AU2006316607A1 (en) 2007-05-31
ZA200804355B (en) 2009-04-29
ZA200804305B (en) 2009-04-29
WO2007061739A2 (en) 2007-05-31
CA2629560A1 (en) 2007-05-31
CN101312730A (zh) 2008-11-26
TW200738240A (en) 2007-10-16
WO2007061828A2 (en) 2007-05-31
WO2007061828A3 (en) 2007-07-19
NZ568313A (en) 2011-11-25
AR058193A1 (es) 2008-01-23
JP2009516687A (ja) 2009-04-23
WO2007061739A3 (en) 2007-07-12
JP2009516686A (ja) 2009-04-23
US20070116730A1 (en) 2007-05-24
EP1954275A2 (en) 2008-08-13
BRPI0618891A2 (pt) 2011-09-13
EP1951240A2 (en) 2008-08-06
RU2008124805A (ru) 2009-12-27
NO20082833L (no) 2008-07-29
KR20080071185A (ko) 2008-08-01

Similar Documents

Publication Publication Date Title
PE20070643A1 (es) Composiciones farmaceuticas que comprenden buprenorfina
PE20081361A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
PE20140936A1 (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
JP5184342B2 (ja) 外用の医薬組成物
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
AR070083A1 (es) Composiciones y metodos para tratar enfermedades de la una
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
PE20081114A1 (es) Composiciones farmaceuticas bioadhesivas de agente dual para uso topico
MA33356B1 (fr) Compose anticancereux et composition pharmaceutique le contenant
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
ATE489942T1 (de) Ternäre nichtlamellare lipidzusammensetzungen
NO20025629D0 (no) Formulering
JPWO2007102242A1 (ja) 外用の医薬組成物
AR069572A1 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
CN101808641A (zh) 含有吡菲尼酮的凝胶
JP2010509292A5 (es)
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
JP2020508992A (ja) ざ瘡の処置のためのカンナビノイドの製剤
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR056471A1 (es) Formulaciones de acetato de bazedoxifeno
EP3058945A2 (en) Pharmaceutical compositions and formulations for topical application with astringent and antimicrobial effect
AR064262A1 (es) Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
PE20080149A1 (es) Formulacion liquida acuosa que comprende un beta bloqueador
PE20130814A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
CA2623345A1 (en) Fulvestrant formulation

Legal Events

Date Code Title Description
FC Refusal